Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087399 · ClinicalTrials.gov registry record · Phase 3

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
118
Enrollment target

NCT00087399 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 118 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087399, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
118 participants
Enrollment target

Study Summary

RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes. PURPOSE: This randomized phase III trial is studying gabapentin and antidepressants to see how well they work compared to antidepressants alone in treating hot flashes in women who have had breast cancer or who have concerns about taking hormones to treat hot flashes.

Interventions

  • DRUG gabapentin
  • DRUG antidepressant

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2004-11
Est. Completion 2007-04
Phase Phase 3

What the Registry Record Tells You About NCT00087399

The ClinicalTrials.gov registry entry for NCT00087399 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which gabapentin is the first listed.

NCT00087399 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00087399 about?

NCT00087399 is a clinical study titled "Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy". RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes. PURPOSE: This...

What is the current status of trial NCT00087399?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2004-11. Estimated completion is 2007-04.

What interventions are being tested in trial NCT00087399?

The interventions under investigation include: gabapentin (DRUG), antidepressant (DRUG).

Who is sponsoring clinical trial NCT00087399?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.